Leyden Laboratories Secures €30M In Equity Funding

The funding round, led by the European Innovation Council (EIC) Fund and Invest-NL, will allow Leyden Laboratories to advance clinical trials for its pan-influenza nasal spray (PanFlu) and further develop its wider pipeline of mucosal therapies.

Led by CEO Koenraad Wiedhaup and CFO Marieke van der Lans Leyden Labs develops nasal sprays that target airborne respiratory viruses at their entry point. By delivering broadly protective antibodies directly to the respiratory mucosa, these sprays offer immediate protection including for individuals with weakened immune systems.

Read Also - EIT Governing Board Approves €978 Million To Boost Innovation And Skills Across Europe

"With PanFlu, we are taking a bold step to stop influenza viruses at the gate. We are proud to welcome these two esteemed European funds, each with the goal of accelerating innovations in Europe that deliver public benefit. Their support for our strategy to develop novel products to protect against respiratory viruses is a wonderful endorsement of our relentless efforts," said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs.

Founded in 2020, Leyden Labs is dedicated to helping people live life to the fullest by protecting against known and emerging respiratory viruses.

Their platform targets shared features of viral families, developing accessible intranasal products that offer immediate protection and help prevent the spread of influenza, coronavirus and other respiratory viruses. With a team of experienced biotechnology experts and innovative talent, Leyden Labs is committed to pioneering new approaches that reduce the global impact of respiratory infections and empower people to stay healthy.